Vyome announces plans to go public, trade on Nasdaq Capital Market

Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, announced that it has signed a merger agreement with ReShape Lifesciences. Upon closing, it is anticipated that the post-merger entity, will be renamed Vyome Holdings, Inc., and continue to have its common stock traded on Nasdaq under the new ticker symbol “HIND.” As part of this transaction, Vyome announced that Ambassador Frank Wisner will be joining its Board of Directors at closing. Chardan is serving as financial advisor to Vyome and Sichenzia Ross Ference Carmel LLP is acting as its legal counsel for both the merger and the concurrent financing transaction. Maxim Group LLC is serving as financial advisor to ReShape and Fox Rothschild LLP is acting as its legal counsel. Under the terms of the merger agreement, a newly formed wholly owned subsidiary of ReShape will merge with and into Vyome, with Vyome continuing as the surviving corporation and wholly owned subsidiary of ReShape. The closing of the merger is subject to certain closing conditions including, among other things, approval by the stockholders of ReShape and Vyome, the Securities and Exchange Commission declaring effective ReShape’s registration statement registering the shares to be issued in connection to the merger, and the Nasdaq Stock Market’s approval of the continued listing of the common stock of the combined company.